GH Research Reports Positive Phase 2b TRD and Phase 2a Bipolar II Depression Trial Results for GH001
GHRS has more than doubled off its 52-week low of $7.98 on elevated volume (4.3× avg).
Summary
GH Research announced positive clinical trial results for its lead candidate GH001 in both Treatment-Resistant Depression (Phase 2b) and Bipolar II Disorder (Phase 2a), demonstrating efficacy and a favorable safety profile.
Key Events · Product Development and Regulatory · GHRS
-
Positive Phase 2b TRD Results
GH001 met its primary endpoint in a Phase 2b trial for Treatment-Resistant Depression, showing a significant reduction in MADRS total score (-15.5 vs placebo) and high remission rates (57.5% at Day 8, 73% at 6 months).
-
Favorable Safety Profile in TRD
The TRD trial demonstrated that GH001 was well tolerated, with no increase in suicidal ideation or behavior, addressing a critical safety concern for depression treatments.
-
Promising Phase 2a Bipolar II Depression Results
A Phase 2a trial for Bipolar II Disorder met its primary endpoint, showing rapid antidepressant effects and a favorable safety profile without inducing manic symptoms.
-
Pipeline Advancement
These results collectively advance GH001's development in multiple indications, validating its therapeutic potential and expanding its market opportunity.
Analysis · GHRS · Life Sciences
The filing details strong clinical data for GH001 across two indications, significantly de-risking the lead asset. The Phase 2b trial in Treatment-Resistant Depression (TRD) met its primary endpoint with substantial reductions in depressive symptoms and high remission rates, alongside a favorable safety profile, notably without increasing suicidal ideation. The Phase 2a trial in Bipolar II Disorder (BDII) also showed rapid antidepressant effects and a good safety profile without inducing manic symptoms, opening up a new potential market. These results provide strong validation for GH001's therapeutic potential and advance its development pipeline.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1052 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GHRS was trading at $17.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $7.98 to $20.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.